Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — Shareholder Meeting (April 2026)
16 slides from Bristol-myers Squibb's shareholder meeting presentation, Apr 17, 2026
Slide 1: Proxy Season Update April 2026
Proxy Season Update April 2026
Slide 2: Our Mission, Vision and Values
2 Our Mission To discover, develop and deliver innovative medicines that help patients prevail over serious diseases Our Vision To be the world's leading biopharma company that transforms patients' lives through science Our Values Innovation Passion Inclusion Accountability Integrity Urgency
Slide 3: 2025 Clinical and Regulatory Achievements
Building a company that is financially strong and delivers industry-leading sustainable growth into the 2030s and beyond. 3 Continued Pipeline Progress 18 Approvals in the U.S., E.U., Japan & China 13 Submissions to the FDA and other markets 10 IND/CTA approvals 25+ Early-stage assets In 2025, our C
Slide 4: Delivering Sustainable Growth & Innovation
Delivering Sustainable Growth & Innovation 4 * Growth Portfolio includes: Opdivo® (nivolumab), Opdivo QvantigTM (nivolumab and hyaluronidase-nvhy), Orencia® (abatacept), Yervoy® (ipilimumab), Reblozyl® (luspatercept-aamt), Breyanzi® (lisocabtagene maraleucel), Opdualag® (nivolumab and relatlimab-rmb
Slide 5: Committed to Sound Corporate Governance
Committed to Sound Corporate Governance 5 Board Accountability and Shareholder Rights Regular shareholder engagement Annual election of Directors Majority voting standard for election of Directors Robust Lead Independent Director role Annual performance reviews for the board and committees, and indi
Slide 6: Robust Role of Lead Independent Director
Robust Role of Lead Independent Director 6 Serving as liaison between the independent Directors and the Board Chair and Chief Executive Officer Reviewing and approving meeting agendas and sufficiency of time Calling meetings of the independent Directors Presiding at all meetings of the independent D
Slide 7: Board Nominees
Christopher S. Boerner, Ph.D. Theodore R. Samuels Peter J. Arduini Deepak L. Bhatt, M.D., M.P.H., M.B.A. Julia A. Haller, M.D. Manuel Hidalgo Medina, M.D., Ph.D. Board Chair & Chief Executive Officer of the Company Lead Independent Director (C) (C) (C) More than 20 years of experience in the biotech
Slide 8: Our Board Nominees Have a Comprehensive Collection of Varied Backgrounds
Our Board Nominees Have a Comprehensive Collection of Varied Backgrounds, Industry Experiences & Personal Characteristics 8 Healthcare Experience in relevant areas within the healthcare industry, including science, manufacturing, regulatory compliance, payer dynamics, and working with health care pr
Slide 9: Executive Compensation Supporting our Core Strategy
Executive Compensation Supporting our Core Strategy 9 92% 80% of target pay is performance-based and at risk of target pay delivered in long-term equity Incentives with three-year cliff vesting 85% 70% of average NEO target pay is performance-based and at risk of average NEO target pay delivered in
Slide 10: 2025 Executive Compensation Program
2025 Executive Compensation Program:Supporting Revenue Renewal and Execution of Our Core Strategy1 10 Base Salary Based on specialized qualifications, experience and role impact, pay levels of comparable positions within peer group and competitive market Annual Incentive (Paid in cash) Non-GAAP Oper
Slide 11: Executive Compensation Governance Practices
Executive Compensation Governance Practices 11 What We Do: What We Do Not Do: 100% performance-based annual and long-term incentives X Provide guaranteed incentives Caps on the payouts under our annual and long-term incentive award programs X Allow speculative and hedging transactions Robust s
Slide 12: 2026 Board Recommendations
12 2026 Bristol Myers Squibb Board recommendations: Management Proposals Shareholder Proposal FOR Election of Directors AGAINST Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director FOR Advisory Vote to Approve the Compensation of our Nam
Slide 13: Management Proposal on the 2026 Stock Award and Incentive Plan
13 Accordingly, the Board of Directors unanimously recommends a vote “FOR” this proposal. Management Proposal on the Approval of the Company’s 2026 Stock Award and Incentive Plan The 2026 Plan is an “omnibus” plan, authorizing a variety of equity award types as well as cash incentive awards. The 202
Slide 14: Shareholder Proposal on Independent Board Chair
14 Accordingly, the Board of Directors unanimously recommends a vote “AGAINST” this shareholder proposal. Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director The Board has carefully considered this proposal and believes the actions requ
Slide 15: Forward-Looking Statements
15 This presentation (as well as the oral statements made with respect to information contained in this presentation) contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials results, and regu
Slide 16: Bristol Myers Squibb
(lh Bristol Myers Squibb’
Bristol Myers Squibb — Shareholder Meeting (April 2026) on 6ix